Introduction: Canakinumab is an IL-1β selective human monoclonal antibody in IgG structure used in autoinflammatory diseases and systemic juvenile idiopathic arthritis (SJIA) treatment. Here, IL1B is linked to systemic-onset juvenile idiopathic arthritis.